Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

(2013) Niels Vande Casteele et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis

(2012) Kavinderjit S Nanda et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease

(2012) Shomron Ben–Horin et al.   Clinical Gastroenterology and Hepatology

Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms

(2012) I Ordás et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease

(2011) Nicholas J Talley et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

(2011) Edouard Louis et al.   GASTROENTEROLOGY

Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease

(2011) Benjamin Pariente et al.   INFLAMMATORY BOWEL DISEASES

Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease

(2011) Jean-Frédéric Colombel et al.   INFLAMMATORY BOWEL DISEASES

Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease

(2011) Hirotsugu Imaeda et al.   JOURNAL OF GASTROENTEROLOGY

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

(2010) Waqqas Afif et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful

(2010) S. Ben-Horin et al.   GUT

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

(2009) C H Seow et al.   GUT